Abstract

The endocannabinoid system, with its receptors and ligands, is present in the gut epithelium and enteroendocrine cells, and is able to modulate brain functions, both indirectly through circulating gut-derived factors and directly through the vagus nerve, finally acting on the brain's mechanisms regarding metabolism and behavior. The gut endocannabinoid system also regulates gut motility, permeability, and inflammatory responses. Furthermore, microbiota composition has been shown to influence the activity of the endocannabinoid system. This review examines the interaction between microbiota, intestinal endocannabinoid system, metabolism, and stress responses. We hypothesize that the crosstalk between microbiota and intestinal endocannabinoid system has a prominent role in stress-induced changes in the gut-brain axis affecting metabolic and mental health. Inter-individual differences are commonly observed in stress responses, but mechanisms underlying resilience and vulnerability to stress are far from understood. Both gut microbiota and the endocannabinoid system have been implicated in stress resilience. We also discuss interventions targeting the microbiota and the endocannabinoid system to mitigate metabolic and stress-related disorders.

MeSH

Microbiota, Brain, Stress, Physiological, Endocannabinoids

Cited by

• Biomolecular Actions by Intestinal Endotoxemia in Metabolic Syndrome. Int J Mol Sci, 2024
• Parental Social Isolation during Adolescence Alters Gut Microbiome in Rat Male Offspring. Biomolecules, 2024
• Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis. Front Endocrinol (Lausanne), 2023
• Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy. Front Immunol, 2025
• Consumption of dietary emulsifiers increases sensitivity to social stress in mice: A potential role for the COX molecular pathway. Horm Behav, 2025
• Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease. Pharmaceuticals (Basel), 2025
• Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. Br J Cancer, 2024
• Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 Supplementation: An Exploratory, Randomized, Placebo-Controlled Trial of Endocannabinoid and Inflammatory Responses in Female Dancers. Microorganisms, 2025
• Emerging mechanisms of organ crosstalk: The role of oxylipins. Nutr Bull, 2025
• Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health. Med Cannabis Cannabinoids, 2023
• The Bidirectional Interplay Between Substances of Abuse and Gut Microbiome Homeostasis. Life (Basel), 2025
• Got the Munchies for an Egg Sandwich? The Effects of Cannabis on Bowel Motility and Beyond. J Nucl Med Technol, 2024
• Buds and Bugs: A Fascinating Tale of Gut Microbiota and Cannabis in the Fight against Cancer. Int J Mol Sci, 2024
• Hemp Extract () in the Treatment of Gastrointestinal Distress and Dyspepsia: Historical Insights from Barcelona, Spain. Pharmaceuticals (Basel), 2025
• Pharmacological potential of endocannabinoid and endocannabinoid-like compounds in protecting intestinal structure and metabolism under high-fat conditions. Front Pharmacol, 2025